Ang Lifesciences India Ltd (BSE: 540694) is a Amritsar, Punjab-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹49 Cr, it ranks #3,866 by market cap among the 6,137 Indian listed companies on FinBizNet, and #75 of 86 in Medicinal Chemicals and Botanical Products. At ₹33.00 (as of 25 Oct 2026), the share price is 33.6% below its 52-week high of ₹49.69 and 87.2% above its 52-week low of ₹17.63. The share price is up 7.2% over one year and down 8.2% over three months.
| Current Price | ₹33.00 |
|---|---|
| Market Cap | ₹49 Cr |
| BSE Code | 540694 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -4.4 |
| Return on Equity | -17.70% |
| Return on Assets | -1.45% |
| 52-Week Range | ₹17.63 – ₹49.69 |
| 1-Year Price Change | +7.2% |
| 3-Month Price Change | -8.2% |
| Beta (1Y) | -0.55 |
| Dividend Yield | 0.00% |
| Headquarters | Amritsar, Punjab |
| Website | anglifesciences.com |
| Revenue | ₹14 Cr |
|---|---|
| Net Profit | ₹-3 Cr |
| Net Margin | -24.5% |
| EPS (Basic) | ₹2.59 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
ANG Lifesciences India Limited engages in manufacturing and sale of finished pharmaceutical formulations in India and internationally. Its product portfolio comprises therapeutics categories, such as antibiotics, antiviral, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, and beta lactamase inhibitor. The company offers its finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, and lotions. ANG Lifesciences India Limited was incorporated in 2006 and is based in Amritsar, India.
1. Pharmaceuticals-This segment engages in the pharmaceutical business. 2. Printing and Packagings-This segment engages in the printing and packaging business. 3. Inter Segment Revenue-0
1. Pharmaceuticals-98.6% 2. Printing and Packagings-5.2%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Ang Lifesciences India Ltd | ₹49 Cr | -4.4 | -17.70% | ₹14 Cr | +7.2% |
Listed by market capitalisation. Ratios are shown for context only.
Ang Lifesciences India Ltd is trading at ₹33.00, with a market capitalisation of ₹49 Cr.
Ang Lifesciences India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ang Lifesciences India Ltd has a P/E of -4.4 and a return on equity of -17.70%.
Ang Lifesciences India Ltd is listed on the BSE under the scrip code 540694.
Ang Lifesciences India Ltd's share price is up 7.2% over one year and down 8.2% over three months. Its 52-week range is ₹17.63 to ₹49.69.
In Q1 FY27, Ang Lifesciences India Ltd reported revenue of ₹14 Cr and net profit of ₹-3 Cr, with basic EPS of ₹2.59 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.